ADEBOLA AJANAKU: Open Payments
NPI 1669927224 · UNION, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$833 in 44 payments from 11 companies in 2025. Trend: 2023 $762 · 2024 $820 · 2025 $833
Food & beverage: $833
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $249 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $117 |
| Janssen Pharmaceuticals, Inc | 5 | $83 |
| Teva Pharmaceuticals USA, Inc. | 5 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Alkermes, Inc. | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 3 | $50 |
| ABBVIE INC. | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 3 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
Products named: INGREZZA, CAPLYTA, INVEGA SUSTENNA, UZEDY, ARISTADA, COBENFY, REXULTI, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
